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Abstract
There are over 70 human diseases that are caused by defects in various aspects of lysosomal function. Until 20
years ago, the only specific therapy available for lysosomal storage disorders was allogeneic haemopoietic
stem cell transplantation. Over the last two decades, there has been remarkable progress and there are
now licensed treatments for seven of these diseases. In some cases, a choice of agents is available. For
selected enzyme-deficiency disordes, ERT (enzyme-replacement therapy) has proved to be highly effective.
In other cases, ERT has been less impressive, and it seems that it is not possible to efficiently deliver
recombinant enzyme to all tissues. These difficulties have led to the development of other small-molecule-
based therapies, and a drug for SRT (substrate-reduction therapy) is now licensed and potential chaperone
molecules for ERT are in the late stages of clinical development. Nonetheless, there is still significant unmet
clinical need, particularly when it comes to treating LSDs which affect the brain. LSDs have led the way in the
development of treatment for genetic disorders, and it seems likely that there will be further therapeutic
innovations in the future.
Introduction
The LSDs (lysosomal storage disorders) are a group of
inherited metabolic diseases in which pathology results from
the accumulation of undegraded macromolecules within the
cell. Although the majority of these diseases are caused by
deficiency in the activity of acid hydrolases, others involve
the targeting and activation of these proteins or trafficking
of molecules in and out of the lysosome. LSDs are extremely
variable in their clinical features: the effects of storage depend
on the nature of the storage molecule and the cells and tissues
in which it accumulates. In many cases, lysosomal storage
triggers a complex cascade of downstream events which can
eventually affect cells and tissues in which storage itself is
not evident and the pathogenesis of these disease is not fully
understood.
Over the last 40 years, there has been remarkable
therapeutic innovation in the LSD field, and LSDs have
become the prototype for developing treatment for genetic
diseases. The demonstration by Elizabeth Neufeld that
conditioned medium from cells from patients with one LSD
could lead to the correction of storage in cells from a patient
with a different LSD started this process [1]. This observation
led to the elucidation of how enzymes are targeted to
the lysosomal compartment by the mannose 6-phosphate
receptor and the demonstration that this receptor was also
present on the surface of the cell, allowing the uptake of
enzyme from outside the cell.
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Enzyme-augmentation therapy
The initial approaches to treating LSDs involved attempts to
restore degradative activity by providing exogenous enzyme,
which could then be taken up into the cell via the mannose
6-phosphate receptor pathway.
Allogeneic BMT (bone marrow transplantation)
The aim of BMT is to use the donor bone-marrow-derived
cells as a source of enzyme. In particular, donor macrophages
should be able to infiltrate the patients tissues and act as
miniature enzyme factories, secreting a cocktail of lysosomal
hydrolases which can then correct a variety of lyso-
somal deficiencies in surrounding host cells [2].
The first BMTs for LSDs were performed in children with
Hurler disease [MPS (mucopolysaccharidosis) I)] in the early
1980s [3]. Although no formal clinical trial has been con-
ducted, several hundred procedures have subsequently been
carried out in this condition, and the place of BMT is now
well established. Visceral disease improves. Skeletal disease
persists, but may progress more slowly. If transplantation
is performed early enough (generally before 2 years of age),
then neurological disease may stabilize. This is because the
brain is gradually repopulated with microglia of donor origin,
which then provide a source of enzyme within the brain,
thus circumventing the BBB (blood–brain barrier) which
stops circulating enzyme from entering the CNS (central
nervous system).
It was hoped that this paradigm would prove successful
in a range of other LSDs. Unfortunately this has not turned
out to be the case. In MPS II (Hunter disease) and MPS
III (Sanfilippo disease), there was no discernable effect of
BMT on cognitive decline. In MPS IV (Morquio disease)
the skeletal involvement, which is the main feature, does
not respond to BMT. There does appear to be a place for
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BMT in the management of the lysosomal leucodystrophies,
MLD (metachromatic leucodystrophy) and Krabbe disease,
but only if performed early. This is because it takes from 6
months to 1 year for donor microglia to enter the brain in
sufficient quantities to provide metabolic cross-correction
and the disease continues to progress throughout this
period [4].
Surprisingly, BMT has not established a role in the LSDs
which are characterized by visceral disease without skeletal or
CNS involvement. To some extent, this has been because these
diseases tend to affect patients later on in life. In these older
patients, BMT has a much higher morbidity and mortality.
In the case of type 1 Gaucher disease, the commonest of the
LSDs, the advent of ERT (enzyme-replacement therapy) has
removed the need for BMT. In some of the other rarer diseases
such as Niemann–Pick type B disease or fucosidosis, where
no other treatment is currently available, it may be worth
reconsidering BMT, particularly as the procedure itself now
appears to be much safer.
Enzyme-replacement therapy
ERT was originally developed for Gaucher disease using
glucocerebrosidase purified from human placentas. With
the advent of molecular genetics, this was replaced by
a recombinant product made in tissue culture. ERT for
Gaucher disease has been a great success story. The visceral
manifestations of Gaucher disease are primarily due to storage
in macrophages. Enzyme administered intravenously is
readily taken up by these cells and there is rapid resolution of
hepatomegaly and splenomegaly. Haematological parameters
improve and patients feel much better.
ERT is not a cure for Gaucher disease; established bone
disease does not respond well to therapy and the enzyme
does not cross the BBB and cannot affect the neurological
manifestations of neuronopathic disease. Patients require
lifelong treatment, although experience with a recent global
shortage of product has shown that, for many individuals,
the intensity of treatment can probably be significantly
reduced once the disease has been stabilized. For the vast
majority of people with type 1 Gaucher disease, ERT is a
life-transforming treatment.
The success of ERT in Gaucher disease led to the
development of a similar approach for other LSDs, and
licensed products are now available for Gaucher disease,
Fabry disease, MPS I, MPS II, MPS VI and Pompe disease.
It is fair to say that, although all of these treatments have
shown efficacy in clinical trials, none has approached the
effect of imiglucerase in Gaucher disease. This is probably
because the cell types and tissues involved in these diseases
(the heart and kidney in Fabry disease, bone in the MPSs
and muscle in Pompe disease) are much less accessible to
intravenously delivered enzyme than are macrophages. Many
of the manifestations of established disease do not respond to
ERT and, in some instances (e.g. renal impairment in Fabry
disease), there is continued progression despite therapy. For
these conditions, the hope is that very early intervention will
prevent end organ damage and the aim is to identify and treat
patients in childhood. It is likely to be many years before we
know whether this approach has been successful.
Conventional wisdom suggests that a recombinant protein
made by expression of cDNA should be identical with the
endogenous ‘natural’ product. This may be true at the level of
amino acid sequence, but will not hold for post-translational
modifications, which will be specific to the cell type in which
the protein is made. As correct glycosylation is essential for
the proper targeting of lysosomal enzymes, the technology
used to produce individual products could have a profound
effect on their therapeutic efficacy.
The majority of ERT products available are recombinant
proteins made in CHO (Chinese-hamster ovary) cell lines.
The enzymes are purified from cell culture medium and then
treated with exoglycosidases to expose terminal mannose
residues on the oligosaccharide chains. Other products
are made by overexpressing the native gene in a human
cell line in tissue culture, so-called ‘gene activation’, and
these proteins would expect to exhibit a ‘natural’ pattern
of glycosylation. Comparison of crystal structures of
recombinant glucocerebrosidase (imiglucerase) and the gene-
activated form (velaglucerase alfa) confirm that there are real
differences in glycosylation [5] and velaglucerase alfa is taken
up more efficiently by cultured macrophages. Velaglucerase
alfa has recently been licensed; it remains to be seen whether
it will be effective at lower doses than imiglucerase.
A third product, taliglucerase alfa, is also in late stages
of clinical development for use in Gaucher disease. This
is a recombinant glucocerebrosidase made in carrot cells.
Production of recombinant human proteins from plant cells
is much simpler than production from animal cell lines. Cur-
rently available ERT products are prohibitively expensive,
and plant cell technology may lead to substantial cost savings
in the future, although the requirement for pharmaceutical
companies to recoup development costs and make profits
means that drugs for orphan diseases such as the LSDs, where
there are only a few tens of thousands of patients in the world,
will never be cheap.
One major drawback of the ERT approach is that it has no
effect on lysosomal storage in the nervous system. Although
work in some animal models has suggested that it may be
possible to gain entry of enzyme into the brain if sufficiently
large doses are used, there is no evidence to support this
approach in humans. A recent clinical trial investigating
this approach in MLD was terminated because of a lack
of evidence for any effect (http://clinicaltrials.gov identifier
NCT00633139).
An alternative strategy has been to deliver enzyme by
direct injection into the CSF (cerebrospinal fluid) [6]. Results
in animal models are encouraging, but this technology has
not yet been translated to the clinic and would clearly pose
considerable challenges. The lack of efficacy of ERT in
treating CNS and skeletal manifestations of disease, the need
for regular intravenous infusions and its high cost have driven
the search for alternative small-molecule-based approaches to
treating LSDs.
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SRT (substrate-reduction therapy)
LSDs are characterized by a spectrum of disease severity
which correlates, at least in part, with residual enzyme
activity. On the whole, only patients with the most severe,
early-onset and rapidly progressive disease will have two
nonsense mutations and no functional enzyme. The majority
of patients will have at least one allele bearing a missense
mutation that will code for an enzyme which has some
catalytic activity.
In SRT, the aim is to reduce the concentration of the
accumulating substrate of a deficient enzyme or process. This
approach is familiar to those treating inherited metabolic
diseases; it underlies the use of dietary treatment for
phenylketonuria and other aminoacidopathies. In LSDs, the
strategy has been to reduce the rate of synthesis of the stored
macromolecule to a level where the residual degradative
enzyme activity can maintain homoeostasis [7].
Miglustat is an inhibitor of the ceramide glucosyltrans-
ferase which catalyses the first step of GSL (glycosphin-
golipid) synthesis. It is therefore a potential treatment for a
variety of LSDs, including Gaucher disease, Fabry disease and
the gangliosidoses, which are devastating neurodegenerative
diseases for which no specific therapy is currently available.
Miglustat has been demonstrated to clear GSL storage in
visceral and CNS cells and to delay symptom onset and
increase survival in a variety of mouse models of these
diseases [8].
Miglustat was first clinically developed as a second-line
therapy in Gaucher disease [9]. Subsequently, a number
of trials have been carried out in neurological storage
disorders [10–12]. These studies have perhaps told us
more about the difficulties of conducting clinical trials in
slowly progressive neurological disorders where there is
considerable interpatient variability and the natural history
of the disease is not well understood [8]. Under these
circumstances, it is very difficult to define hard clinical
end points which will demonstrate significant change over
the relatively short periods over which drug trials are
performed. A 12-month placebo-controlled trial of miglustat
in Niemann–Pick type C disease (in which secondary storage
of gangliosides is important) did, however, demonstrate
stabilization of disease progression, and miglustat is now
licensed in Europe for the treatment of this disease [11].
Other SRT molecules are now being developed. As well
as a second inhibitor of GSL synthesis [13], work has also
started using genistein as an inhibitor of mucopolysaccharide
synthesis [14,15].
Enzyme-enhancement therapy
In the majority of LSDs and many other inherited metabolic
diseases, the disease only becomes clinically evident once
residual enzyme activity falls below 15–20 %. Another
therapeutic approach is to try to enhance the activity of
mutant enzyme. Increasing residual enzyme activity by only
a few per cent may have profound clinical effects.
This approach is well established for a number of vitamin-
dependent enzymes. Homocystinuria, caused by mutations
in the gene coding for CBS (cystathionine β-synthase), can be
effectively treated with pharmacological doses of pyridoxine
(vitamin B6), which is an essential cofactor for the CBS
enzyme. Unfortunately, no suitable cofactors have yet been
identified for lysosomal hydrolases.
Chaperone therapy
Like SRT, chaperone therapy exploits the fact that the
majority of patients will have at least one mutant allele coding
for an intact protein. In many cases, these mutant proteins are
unstable; they are recognized by the cell as being defective and
are targeted to the proteasome for degradation. The aim of
chaperone therapy is to rescue these mutant proteins so that
they can be delivered to the lysosome where they can express
their residual enzyme activity [16].
The first clinical demonstration of chaperone therapy
was in a patient with Fabry disease, where an intravenous
infusion of galactose enhanced enzyme activity and led
to improvements in cardiac function [17]. Subsequent
clinical development has focused on the imino sugar 1-
deoxygalactonojirimycin, which has shown good efficacy in
a mouse model of Fabry disease and is now in late stages of
clinical development [18].
These small molecules are taken orally and should have
better biodistribution than recombinant enzyme. However,
their effects are not only disease-specific, but also are
mutation-specific. In addition, the molecules used tend to
bind the active site of the enzyme to be chaperoned and act
as inhibitors as well as chaperones. Dosing regimens have to
allow time for the pharmacological chaperone to diffuse away
from the enzyme once it reaches the lysosome so that it can
express its residual activity.
It may be that a number of potential pharmacological
chaperones are already available, having been licensed for
other indications. A screen of commercially available drugs
looking at their ability to enhance the activity of β-
hexosaminidase (the enzyme deficient in GM2 gangliosidosis)
identified the anti-malarial drug pyrimethamine as a potent
pharmacological chaperone [19]. This safe and cheap drug
is now being used by clinicians for this devastating and
otherwise untreatable condition.
Future developments
Over the last 20 years, we have gone from a situation where
there were no specific treatments for LSDs to one where
there are three different licensed drugs to treat Gaucher
disease (two products for ERT and one for SRT), with a
further two in clinical development (one for ERT and one for
SRT). Similarly, there are two licensed ERT treatments for
Fabry disease, and a pharmacological chaperone is in clinical
development. Nonetheless, there is still considerable unmet
need. With the exception of type 1 Gaucher disease, currently
available treatments are of limited efficacy. The options for
treating neurological and skeletal disease are limited. For the
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vast majority of the more than 70 LSDs, there is still no
specific treatment.
Fortunately, due in part to the ready availability of
animal models, many laboratories continue to work on
these problems, and there are many other approaches in
the pipeline. Inflammation seems to have an important role
in the pathophysiology of many of these diseases, and, in
mice, the use of commonly available anti-inflammatory
agents is synergistic with currently available therapies [20].
Stop-codon readthrough has been successful in mice with
MPS I [21]. There are now few mouse models of LSDs which
have not been successfully treated with gene and stem cell
therapy [22], and these approaches are being adapted to larger
animals [23]. It therefore seems likely that LSDs will continue
to lead the way in developing therapies for genetic disorders.
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